NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-230X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease ; volume:14 ; number:1 ; day:23 ; month:4 ; year:2014 ; pages:1-8 ; date:12.2014
BMC gastroenterology ; 14, Heft 1 (23.4.2014), 1-8, 12.2014

Creator: Del Ben, Maria

Contributor: Polimeni, Licia
Carnevale, Roberto
Bartimoccia, Simona
Nocella, Cristina
Baratta, Francesco
Loffredo, Lorenzo
Pignatelli, Pasquale
Violi, Francesco
Angelico, Francesco
SpringerLink (Online service)

DOI: 10.1186/1471-230X-14-81

URN: urn:nbn:de:1111-2016081214467

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:05 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Del Ben, Maria
Polimeni, Licia
Carnevale, Roberto
Bartimoccia, Simona
Nocella, Cristina
Baratta, Francesco
Loffredo, Lorenzo
Pignatelli, Pasquale
Violi, Francesco
Angelico, Francesco
SpringerLink (Online service)

Other Objects (12)

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease

Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease

Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease

Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model

Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease

Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination

Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease

Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease

Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease

Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model

Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease

Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination

Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease

Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease

Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease

Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model

Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease

Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination

Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease

Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease

Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease

Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model

Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease

Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination

Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease

Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease

Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease

Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model

Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease

Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination

Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease

Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease

Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease

Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model

Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease

Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination

Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

Related objects

Reset password